261 related articles for article (PubMed ID: 14731055)
1. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?
Walley T
CNS Drugs; 2004; 18(1):1-12. PubMed ID: 14731055
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation and decision making in the UK.
Buxton MJ
Pharmacoeconomics; 2006; 24(11):1133-42. PubMed ID: 17067197
[TBL] [Abstract][Full Text] [Related]
3. The role of NICE technology appraisal in NHS rationing.
Walker S; Palmer S; Sculpher M
Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
[TBL] [Abstract][Full Text] [Related]
4. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
5. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
6. NICE methodological guidelines and decision making in the National Health Service in England and Wales.
Gafni A; Birch S; ;
Pharmacoeconomics; 2003; 21(3):149-57. PubMed ID: 12558466
[TBL] [Abstract][Full Text] [Related]
7. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
Towse A
Br J Clin Pharmacol; 2010 Sep; 70(3):360-6. PubMed ID: 20716236
[TBL] [Abstract][Full Text] [Related]
8. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?
Claxton K; Sculpher M; Palmer S; Culyer AJ
Health Econ; 2015 Jan; 24(1):1-7. PubMed ID: 25488707
[TBL] [Abstract][Full Text] [Related]
9. Using health outcomes data to inform decision-making: government agency perspective.
Taylor R
Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
[TBL] [Abstract][Full Text] [Related]
10. Differences in cancer drug assessment between Spain and the United Kingdom.
Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
[TBL] [Abstract][Full Text] [Related]
11. National Institute for Clinical Excellence (NICE): Is economic appraisal working?
Towse A; Pritchard C
Pharmacoeconomics; 2002; 20 Suppl 3():95-105. PubMed ID: 12457430
[TBL] [Abstract][Full Text] [Related]
12. Do NICE and CHI have no interest in safety? Opinion of the book NICE, CHI and the NHS reforms. Enabling excellence or imposing control?
Fletcher P
Adverse Drug React Toxicol Rev; 2000 Aug; 19(3):167-76. PubMed ID: 11059357
[TBL] [Abstract][Full Text] [Related]
13. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
14. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
15. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
16. Decision making by NICE: examining the influences of evidence, process and context.
Cerri KH; Knapp M; Fernández JL
Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
[TBL] [Abstract][Full Text] [Related]
17. Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence.
Jarosławski S; Toumi M
Appl Health Econ Health Policy; 2011 Jul; 9(4):209-15. PubMed ID: 21682349
[TBL] [Abstract][Full Text] [Related]
18. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
20. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
Trowman R; Chung H; Longson C; Littlejohns P; Clark P
Clin Cancer Res; 2011 Aug; 17(15):4930-5. PubMed ID: 21791636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]